Drug makers face sweeping distribution overhaul

China launches a “Two-Invoice System” to simplify the drug distribution chain and reduce prices and corruption in the healthcare sector. The new policy may bring substantial compliance and business model challenges for pharmaceutical companies

17 minute read April 06, 2017 at 05:32 AM

Katherine Jo and clp articles

Drug makers face sweeping distribution overhaul

The Chinese government has announced a new policy to fundamentally reduce marked-up prices and corruption in multi-tier distribution chains.

Exclusive Content

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

Access to 3000+ essential documents, including key PRC laws translated into English
Newsletters with business-critical and sector-specific updates
Premium mobile access with timely analysis on China’s fast-changing market

Already a Subscriber? Log In Here

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)